Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. - Powerful Science for Life
Corporate - Media & Press – H1N1 Flu Test Press Release
Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip
FOR IMMEDIATE RELEASE: April 30, 2009 8:00 am EDT
SUNNYVALE, Calif., April 30 /PRNewswire-FirstCall/ -- Arrayit Corporation (OTC Bulletin Board: ARYC - News), a leading manufacturer of products and services for disease prevention, treatment and cure, announced today that it is developing a microarray-based diagnostic test to detect the H1N1 swine flu virus.
The Arrayit test will allow researchers and clinicians to detect the presence of the virus in infected patients and livestock and to distinguish the threatening mutated strain from less harmful variants in humans and swine. Using its state-of-the-art manufacturing facility, Arrayit plans to begin mass production of its test kits over the next several weeks. The H1N1 test kits will be sent to the Centers for Disease Control (CDC) for validation, then sold for emergency use by licensed clinics, laboratories and other health care organizations worldwide.
The 2009 swine flu outbreak has raised concerns at the CDC and the World Health Organization (WHO). The CDC and WHO believe that the current outbreak poses a pandemic risk because the H1N1 flu virus contains genetic elements from both the swine and human influenza viruses, allowing direct human-to-human transmission without the need for agricultural contact. The dangerous 2009 strain has little immunity in the human population, resistance to several common anti-viral drugs, and has caused serious illness and death.
Department of Health and Human Services spokesperson said, "In the event of an emerging pandemic, the CDC-IRR (Influenza Reagent Resource) will serve as a source of reagents for qualified laboratories to provide additional support. During a pandemic, laboratories will play a critical role in detecting and confirming initial cases, characterizing viruses, monitoring the progression of the pandemic, and selecting vaccine strains. Scientists around the world are concerned that the influenza virus could one day mutate and acquire the properties needed to quickly spread between people, resulting in a pandemic."
Arrayit's unique microarray platform allows the design, manufacture and distribution of H1N1 chip technology quickly and inexpensively, owing to the Company's unique and patented contact printing technology, versatile system architecture, and broad customer base. "Our team is able to leverage the most sophisticated and accurate gene testing available on the market today to rapidly and affordably bring this H1N1 flu chip test to market," said Rene Schena, Chief Executive Officer of Arrayit Corporation.
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.
Safe Harbor Statement
Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. The factors include, but are not limited to, risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2008 and Form 10-Q for the fiscal third quarter ended September 30, 2008.
Copyright 1993-2019 Arrayit Corporation. All rights reserved.